Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2018
Reporting Period: Second quarter ended June 30, 2018
This filing serves as a notification that the Company issued a press release regarding its financial results for the second quarter of 2018. The detailed financial data is contained in the press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) but are not present in the body of this 8-K filing.
Material Changes
No specific material changes or comparative financial data versus the prior period are disclosed in this text. The filing directs investors to the press release for the results of operations and financial condition.
Guidance, Outlook, and Risks
- Conference Call: The Company scheduled a conference call for August 8, 2018, at 9:00 a.m. Eastern Time to present the financial results. A live webcast was available on the Company's website.
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties.
- Risk Factors: Investors are directed to Item 1A ("Risk Factors") in the Annual Report on Form 10-K for the fiscal year ended December 31, 2017, and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, for a detailed discussion of risks.
- Legal Disclaimer: Information in Item 2.02 is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific Q2 2018 revenue, net loss, and cash position figures.
- Verify the details of the conference call and webcast archive on the Company's website.
- Consult the Form 10-K (filed March 1, 2018) and Form 10-Q (filed May 10, 2018) for comprehensive risk factors.
- Confirm that no specific financial numbers are present in this 8-K text and that all quantitative data resides in the referenced exhibit.